Australia
From 2023, Juniper was cited in multiple reports examining the regulation of telehealth-based weight-loss services in Australia. The Royal Australian College of General Practitioners (RACGP) and medical regulators raised concerns about prescribing models relying on asynchronous or questionnaire-based assessments for injectable weight-loss medications.[5][15][10] The TGA assessed whether online advertising by Juniper (and it's competitors) could indirectly promote prescription-only medicines in breach of federal law. Between 2022 and 2024 they requested the removal of thousands of unlawful advertisements.[2] In response to updated guidance from the Medical Board of Australia (MBA) restricting "tick-and-flick" prescribing, Eucalyptus Health said that its platforms would comply with requirements for real-time clinical consultation and enhanced verification.[16][15][17]
In July 2023, the TGA opened an investigation into whether email communications sent by Juniper to people on its contact list about the availability of Ozempic constituted unlawful advertising.[18][19]
Through 2024, the TGA proposed the removal of GLP-1 medicines from pharmacy compounding exemptions due to concerns that telehealth prescribing models were inconsistent with exemptions intended for individual patient use. They warned that compounded GLP-1 products were not subject to the same safety, quality, or adverse-event reporting requirements as TGA-approved medicines. Juniper was one of the companies prescribing them. Subsequently, the Australian government banned pharmacy compounding of GLP-1 medicines, requiring all providers to transition their patients to approved commercial products.[8][20][21][22][23]
In November 2024, Australian regulators and medical experts examined whether advertising by Juniper could indirectly promote prescription-only medicines in breach of the TGA rules. It referred to the use of "medical weight-loss programs" without naming specific drugs, in their advertising. Clinicians and eating-disorder advocates called for stricter oversight of direct-to-consumer marketing in the sector.[24]
In 2025, Juniper was among providers whose promotional activity was flagged, including the use of Black Friday sales campaigns and social media engagement. Professional commentary raised concerns about the potential misuse of GLP-1 medications among patients with eating-disorder vulnerabilities.[1][25] The Australian Health Practitioner Regulation Agency (AHPRA) confirmed that it had taken disciplinary action against individual healthcare practitioners for inappropriate prescribing of GLP-1 receptor agonists to patients, including the issuance of cautions and conditions on registration. During the same period, the TGA requested the removal of more than 3,000 online advertisements for weight-loss medicines, issuing infringement notices for unlawful advertising in September 2025, and releasing updated social-media advertising guidance in November 2025.[26]
United Kingdom
In November 2023, Juniper was among several UK-registered online providers continuing to prescribe Ozempic for weight loss during a national shortage of semaglutide.[27]
The Advertising Standards Authority (ASA) issued an advice notice to Juniper over advertisements implying endorsement by National Health Service (NHS) workers. There were concerns about misleading claims and the promotion of prescription-onlu medicines. The ASA launched multiple investigations into online advertising by weight-loss providers, including Juniper.[28][29]
In June 2025, Juniper was among providers examined after test purchases showed weight-loss injections could be obtained following online questionnaires without real-time consultation.[30]
In September 2025, the growing private market for GLP-1 weight-loss medications in the UK had raised concerns about a two-tier system of access, with most users paying privately due to limited NHS availability. Juniper was offering private access to weight-loss treatments, while clinicians and public-health experts warned that cost barriers could exacerbate health inequalities and limit access for lower-income patients.
